My Treatment Approach: Bispecifics in Multiple Myeloma: Translating Evidence to Clinical Practice

Centering discussion on real-world patient scenarios, expert hematologist-oncologists review recent treatment advances in multiple myeloma with a focus on bispecifics and their impact on clinical practice.

EP. 1: Patient Scenario 1: A 66-Year-Old With Triple-Class Refractory MM

May 26th 2022

Expert hematologist-oncologist Adriana Rossi, MD, shares a real-world patient scenario of triple-class refractory multiple myeloma managed with novel bispecific antibody therapy.

EP. 2: Triple-Class Refractory MM: Factors in Selecting Optimal Therapy

May 26th 2022

Shared insight on factors that help to determine optimal therapy for patients diagnosed with triple-class refractory multiple myeloma.

EP. 3: MajesTEC-1: Teclistamab in Relapsed or Refractory Multiple Myeloma

June 2nd 2022

Expert perspectives on the MajesTEC-1 trial, a study of BCMA- and CD3-targeted agent teclistamab in relapsed/refractory multiple myeloma.

EP. 4: Patient Scenario 2: A 57-Year-Old With Heavily Pretreated MM

June 2nd 2022

Moving on to the second clinical scenario of multiple myeloma, Luciano Costa, MD, details his care of a heavily pretreated patient.

EP. 5: MonumenTAL-1: Talquetamab in Relapsed or Refractory Multiple Myeloma

June 9th 2022

Comprehensive discussion on the MonumenTAL-1 trial of talquetamab, a GPRC5D- and CD3-targeted agent, in the setting of relapsed/refractory multiple myeloma.

EP. 6: Multiple Myeloma: Sequencing Novel Bispecific and CAR T-Cell Therapies

June 9th 2022

In light of emerging bispecific and CAR T-cell therapies in multiple myeloma, experts consider how they might optimally sequence treatment.

EP. 7: Moving Bispecific and CAR T-Cell Therapies to Earlier Lines of Therapy in MM

June 16th 2022

Luciano Costa, MD, and Adriana Rossi, MD, consider the possibility of earlier-line bispecific and CAR T-cell therapies in multiple myeloma.

EP. 8: Relapsed/Refractory Multiple Myeloma: Future Directions in Care

June 16th 2022

Closing out their discussion on bispecifics in multiple myeloma, expert hematologist-oncologists share practical advice for community physicians alongside their hopes for the future.